David Allison
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2023 |
13,222 |
13,222
|
-
|
|
-
|
Stock Option (right to buy) |
Darren S. Cline
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2023 |
13,222 |
13,222
|
-
|
|
-
|
Stock Option (right to buy) |
Timothy S. Nelson
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2023 |
13,222 |
13,222
|
-
|
|
-
|
Stock Option (right to buy) |
Mahendra Gopaldas Shah
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2023 |
13,222 |
13,222
|
-
|
|
-
|
Stock Option (right to buy) |
Diane E. Wilfong
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2023 |
13,222 |
13,222
|
-
|
|
-
|
Stock Option (right to buy) |
Darren S. Cline
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Apr 2023 |
20,013 |
20,013
|
-
|
|
-
|
Stock Option (right to buy) |
Leonard S. Paolillo
|
Chief Commercial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 Feb 2023 |
50,000 |
50,000
|
-
|
|
-
|
Stock Option (right to buy) |
John Hoekman
|
Chief Scientific Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 Feb 2023 |
42,500 |
42,500
|
-
|
|
-
|
Stock Option (right to buy) |
John H. Leaman
|
Chief Fin. & Business Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 Feb 2023 |
70,000 |
70,000
|
-
|
|
-
|
Stock Option (right to buy) |
Adrian Adams
|
Director, COB, CEO and President |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 Feb 2023 |
200,000 |
200,000
|
-
|
|
-
|
Stock Option (right to buy) |
John H. Leaman
|
Chief Fin. & Business Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
31 Dec 2022 |
10,571 |
0
|
-
|
|
-
|
Restricted Stock Units (RSUs) |
John H. Leaman
|
Chief Fin. & Business Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
31 Dec 2022 |
10,571 |
10,571
|
-
|
|
0
|
Common Stock |
John H. Leaman
|
Chief Fin. & Business Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.75 per share. |
31 Dec 2022 |
3,627 |
6,944
|
-
|
3.7 |
13,601
|
Common Stock |
David Allison
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2022 |
12,789 |
12,789
|
-
|
|
-
|
Stock Option (right to buy) |
Timothy S. Nelson
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2022 |
12,789 |
12,789
|
-
|
|
-
|
Stock Option (right to buy) |
Mahendra Gopaldas Shah
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2022 |
12,789 |
12,789
|
-
|
|
-
|
Stock Option (right to buy) |
H. Stewart Parker
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2022 |
12,789 |
12,789
|
-
|
|
-
|
Stock Option (right to buy) |
Diane E. Wilfong
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Jun 2022 |
12,789 |
12,789
|
-
|
|
-
|
Stock Option (right to buy) |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
29 Mar 2022 |
24,606 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.97 per share. |
29 Mar 2022 |
24,606 |
97,990
|
-
|
2.0 |
48,474
|
Common Stock |
Leonard S. Paolillo
|
Chief Commercial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 Jan 2022 |
40,000 |
40,000
|
-
|
|
-
|
Stock Option (right to buy) |
John Hoekman
|
Chief Scientific Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 Jan 2022 |
35,000 |
35,000
|
-
|
|
-
|
Stock Option (right to buy) |
John H. Leaman
|
Chief Fin. & Business Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 Jan 2022 |
100,000 |
100,000
|
-
|
|
-
|
Stock Option (right to buy) |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 Jan 2022 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (right to buy) |
Adrian Adams
|
Director, COB, CEO and President |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 Jan 2022 |
175,000 |
175,000
|
-
|
|
-
|
Stock Option (right to buy) |
John Hoekman
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
22 Dec 2021 |
20,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
John Hoekman
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. |
22 Dec 2021 |
20,000 |
128,221
|
-
|
1.6 |
32,800
|
Common Stock |
Timothy S. Nelson
|
Director |
Purchase of securities on an exchange or from another person at price $ 10.76 per share. |
19 Nov 2021 |
10,000 |
10,000
|
-
|
10.8 |
107,554
|
Common Stock |
John H. Leaman
|
Chief Fin. & Business Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
19 Oct 2021 |
10,571 |
10,571
|
-
|
|
-
|
Restricted Stock Units (RSUs) |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.95 per share. |
21 Sep 2021 |
53,954 |
73,384
|
-
|
2.9 |
159,164
|
Common Stock |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.97 per share. |
21 Sep 2021 |
14,780 |
14,780
|
-
|
2.0 |
29,117
|
Common Stock |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. |
21 Sep 2021 |
4,650 |
19,430
|
-
|
2.5 |
11,439
|
Common Stock |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
21 Sep 2021 |
53,954 |
29,587
|
-
|
|
-
|
Stock Option (right to buy) |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
21 Sep 2021 |
4,650 |
541
|
-
|
|
-
|
Stock Option (right to buy) |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
21 Sep 2021 |
14,780 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Adrian Adams
|
Director, COB, CEO and President |
Purchase of securities on an exchange or from another person at price $ 15.89 per share. |
18 Aug 2021 |
600 |
20,000
|
-
|
15.9 |
9,532
|
Common Stock |
Adrian Adams
|
Director, COB, CEO and President |
Purchase of securities on an exchange or from another person at price $ 13.81 per share. |
18 Aug 2021 |
17,203 |
17,203
|
-
|
13.8 |
237,506
|
Common Stock |
Adrian Adams
|
Director, COB, CEO and President |
Purchase of securities on an exchange or from another person at price $ 14.91 per share. |
18 Aug 2021 |
2,197 |
19,400
|
-
|
14.9 |
32,751
|
Common Stock |
Adrian Adams
|
Director, COB, CEO and President |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Jul 2021 |
50,000 |
50,000
|
-
|
|
-
|
Stock Option (right to buy) |
Stephen B. Shrewsbury
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Jul 2021 |
50,000 |
50,000
|
-
|
|
-
|
Stock Option (right to buy) |
John H. Leaman
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Jul 2021 |
50,000 |
50,000
|
-
|
|
-
|
Stock Option (right to buy) |
John Hoekman
|
Chief Scientific Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Jul 2021 |
50,000 |
50,000
|
-
|
|
-
|
Stock Option (right to buy) |
Leonard S. Paolillo
|
Chief Commercial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Jul 2021 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (right to buy) |
Diane E. Wilfong
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
11 Jul 2021 |
11,500 |
11,500
|
-
|
|
-
|
Stock Option (right to buy) |
H. Stewart Parker
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
11 Jul 2021 |
11,500 |
11,500
|
-
|
|
-
|
Stock Option (right to buy) |
Mahendra Gopaldas Shah
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
11 Jul 2021 |
11,500 |
11,500
|
-
|
|
-
|
Stock Option (right to buy) |
Timothy S. Nelson
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
11 Jul 2021 |
11,500 |
11,500
|
-
|
|
-
|
Stock Option (right to buy) |
David Allison
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
11 Jul 2021 |
11,500 |
11,500
|
-
|
|
-
|
Stock Option (right to buy) |
John Hoekman
|
Chief Scientific Officer |
|
27 Apr 2021 |
4,253 |
108,496
|
-
|
|
0
|
Common Stock |
John Hoekman
|
Chief Scientific Officer |
|
27 Apr 2021 |
69,657 |
0
|
-
|
|
-
|
Series A-2 Preferred Stock |